Patents by Inventor Urve Toots
Urve Toots has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230340542Abstract: This disclosure provides methods and landing pad constructs for generation of parental cell lines suitable for targeted integration. A method is provided by the parental cell line development; this is, the introduction of binding sites of BPV1 E2 protein to landing pad vectors so that expressed BPV1 E2 protein could locate the vector to transcriptionally active region in the genome. Cells with high expression level of reporter genes are selected for the next stage and will be used in the development of cell lines expressing another recombinant protein by recombination mediated cassette exchange (RMCE). Landing pad constructs include recombination target sites for site-specific recombinases, and therefore, it could be replaced with gene-of-interest expression construct containing the same set of recombination target sites. This yields the generation of producer cell lines with less effort compared to traditional cell line development by random integration.Type: ApplicationFiled: May 10, 2023Publication date: October 26, 2023Inventors: Kadri ÕUNAP, Eva-Maria TOMBAK, Mart TOOTS, Madis JAKOBSON, Mart USTAV, Jr., Kerttu MURUMETS, Urve TOOTS, Andres MÄNNIK, Mart USTAV, Sr.
-
Patent number: 11685936Abstract: This disclosure provides methods and landing pad constructs for generation of parental cell lines suitable for targeted integration. A method is provided by the parental cell line development; this is, the introduction of binding sites of BPV1 E2 protein to landing pad vectors so that expressed BPV1 E2 protein could locate the vector to transcriptionally active region in the genome. Cells with high expression level of reporter genes are selected for the next stage and will be used in the development of cell lines expressing another recombinant protein by recombination mediated cassette exchange (RMCE). Landing pad constructs include recombination target sites for site-specific recombinases, and therefore, it could be replaced with gene-of-interest expression construct containing the same set of recombination target sites. This yields the generation of producer cell lines with less effort compared to traditional cell line development by random integration.Type: GrantFiled: October 17, 2019Date of Patent: June 27, 2023Assignee: Icosagen Cell Factory OÜInventors: Kadri Õunap, Eva-Maria Tombak, Mart Toots, Madis Jakobson, Mart Ustav, Jr., Kerttu Murumets, Urve Toots, Andres Männik, Mart Ustav, Sr.
-
Publication number: 20200123576Abstract: This disclosure provides methods and landing pad constructs for generation of parental cell lines suitable for targeted integration. A method is provided by the parental cell line development; this is, the introduction of binding sites of BPV1 E2 protein to landing pad vectors so that expressed BPV1 E2 protein could locate the vector to transcriptionally active region in the genome. Cells with high expression level of reporter genes are selected for the next stage and will be used in the development of cell lines expressing another recombinant protein by recombination mediated cassette exchange (RMCE). Landing pad constructs include recombination target sites for site-specific recombinases, and therefore, it could be replaced with gene-of-interest expression construct containing the same set of recombination target sites. This yields the generation of producer cell lines with less effort compared to traditional cell line development by random integration.Type: ApplicationFiled: October 17, 2019Publication date: April 23, 2020Applicant: Icosagen Cell Factory OÜInventors: Kadri ÕUNAP, Eva-Maria TOMBAK, Mart TOOTS, Madis JAKOBSON, Mart USTAV, Jr., Kerttu MURUMETS, Urve TOOTS, Andres MÄNNIK, Mart USTAV, Sr.
-
Patent number: 9725486Abstract: A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.Type: GrantFiled: January 13, 2014Date of Patent: August 8, 2017Assignee: Fit Biotech OYInventors: Kai Krohn, Vesna Blazevic, Marja Tähtinen, Mart Ustav, Urve Toots, Andres Männik, Annamari Ranki, Ene Ustav
-
Patent number: 9474800Abstract: The present invention relates to an alphaviral replicase, especially Semliki Forest Virus replicase, or an expression vector encoding an alphaviral replicase, said alphaviral replicase comprising RNA dependent RNA polymerase activity, for use as an immune system modulating adjuvant. The alphaviral replicase may be used in the combination with a vaccine providing an adjuvant function therein, which when present therein will generate an additional boost to the immune response in the subject to whom this combination is administered as compared to when the vaccine alone is administered to a subject in need thereof. The aim of the present invention is to provide an efficient and easy to administer, species-independent adjuvant which will provide advantages to the adjuvants used together with vaccines today.Type: GrantFiled: May 22, 2009Date of Patent: October 25, 2016Assignee: FIT Biotech OYInventors: Kaja Kiiver, Rein Sikut, Urve Toots, Tarmo Mölder, Andres Männik, Mart Ustav, Katrin Kaldma
-
Publication number: 20140234361Abstract: A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.Type: ApplicationFiled: January 13, 2014Publication date: August 21, 2014Applicant: FIT Biotech OyInventors: Kai KROHN, Vesna Blazevic, Marja Tähtinen, Mart Ustav, Urve Toots, Andres Männik, Annamari Ranki, Ene Ustav
-
Publication number: 20130236958Abstract: This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT).Type: ApplicationFiled: January 23, 2013Publication date: September 12, 2013Applicant: ICOSAGEN CELL FACTORY OUInventors: Toomas SILLA, Ingrid TAGEN, Jelizaveta GEIMANEN, Kadri JANIKSON, Aare ABROI, Ene USTAV, Mart USTAV, Tiiu MANDEL, Urve TOOTS, Andres TOVER, Anne KALLING, Radi TEGOVA
-
Patent number: 8377653Abstract: This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT).Type: GrantFiled: July 7, 2010Date of Patent: February 19, 2013Assignee: Icosagen Cell Factory OüInventors: Toomas Silla, Ingrid Tagen, Anne Kalling, Radi Tegova, Mart Ustav, Tiiu Mandel, Urve Toots, Andres Tover, Aare Abroi, Ene Ustav, Jelizaveta Geimanen, Kadri Janikson
-
Publication number: 20110171255Abstract: The present invention relates to an alphaviral replicase, especially Semliki Forest Virus replicase, or an expression vector encoding an alphaviral replicase, said alphaviral replicase comprising RNA dependent RNA polymerase activity, for use as an immune system modulating adjuvant. The alphaviral replicase may be used in the combination with a vaccine providing an adjuvant function therein, which when present therein will generate an additional boost to the immune response in the subject to whom this combination is administered as compared to when the vaccine alone is administered to a subject in need thereof. The aim of the present invention is to provide an efficient and easy to administer, species-independent adjuvant which will provide advantages to the adjuvants used together with vaccines today.Type: ApplicationFiled: May 22, 2009Publication date: July 14, 2011Applicant: Fit Biotech OyInventors: Kaja Kiiver, Rein Sikut, Urve Toots, Tarmo Mölder, Andres Männik, Mart Ustav, Katrin Kaldma
-
Publication number: 20110076760Abstract: This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT).Type: ApplicationFiled: July 7, 2010Publication date: March 31, 2011Applicant: Icosagen S.A.Inventors: Toomas Silla, Ingrid Tagen, Anne Kalling, Radi Tegova, Mart Ustav, Tiiu Mandel, Urve Toots, Andres Tover, Aare Abroi, Ene Ustav, Jelizaveta Geimanen, Kadri Janikson
-
Publication number: 20090252707Abstract: A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.Type: ApplicationFiled: January 27, 2009Publication date: October 8, 2009Applicant: FIT BIOTECH OYInventors: KAI KROHN, VESNA BLAZEVIC, MARJA TAHTINEN, MART USTAV, URVE TOOTS, ANDRES MANNIK, ANNAMARI RANKI, ENE USTAV
-
Patent number: 7521182Abstract: A selection system free of antibiotic resistance genes, which is based on the use of an araD gene as a selection marker carried on a vector which is inserted in a bacterial strain deficient of the araD gene. The araD gene from E. coli encodes the L-ribulose-5-phosphate-4-epimerase. A method of selecting the cells transformed with a plasmid, which contains the araD gene. The non-antibiotic selection marker makes the system suitable for producing therapeutics. The araD gene is not essential for growth of the host but manipulation of it affects the growth under certain selective conditions. Deletion of araD leads to accumulation of substance which is toxic to the host but not to humans. The araD gene is relatively small and therefore a small plasmid may be constructed, which requires less energy for replication, and leads to increased growth rate and yield.Type: GrantFiled: September 15, 2004Date of Patent: April 21, 2009Assignee: FIT Biotech OYInventors: Tanel Tenson, Silja Laht, Maarja Ado-Jaan, Andres Männik, Urve Toots, Mart Ustav
-
Patent number: 7510718Abstract: The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing the vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics containing the vectors, and to therapeutic uses of the vectors. The novel vectors comprise (a) an expression cassette of a gene of a nuclear-anchoring protein, which contains (i) a DNA binding domain capable of binding to a specific DNA sequence and (ii) a functional domain capable of binding to a nuclear component and (b) a multimerized DNA sequence forming a binding site for the anchoring protein, and optionally (c) one or more expression cassettes of a DNA sequence of interest. The vectors lack a papilloma virus origin of replication.Type: GrantFiled: May 3, 2002Date of Patent: March 31, 2009Assignee: Fit Biotech Oyj PLCInventors: Kai Krohn, Vesna Blazevic, Marja Tahtinen, Mart Ustav, Urve Toots, Andres Mannik, Annamari Ranki, Ene Ustav
-
Patent number: 7498314Abstract: The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing said vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics, and to therapeutic uses of said vectors. More specifically, the present invention relates to novel vectors comprising an expression cassette of a gene of a nuclear-anchoring protein, which contains a DNA binding domain capable of binding to a specific DNA sequence and a functional domain capable of binding to a nuclear component and a multimerized DNA sequence forming a binding site for the nuclear-anchoring protein, and optionally an expression cassette of a gene, genes or a DNA sequence or DNA sequences of interest. The present invention further relates to DNA vaccines and gene therapeutics containing the novel vectors, to methods for the preparation of the novel vectors and the DNA vaccines and gene therapeutics.Type: GrantFiled: May 3, 2002Date of Patent: March 3, 2009Assignee: Fit Biotech Oyj PLCInventors: Kai Krohn, Vesna Blazevic, Marja Tähtinen, Mart Ustav, Urve Toots, Andres Männik, Annamari Ranki, Ene Ustav
-
Publication number: 20070036822Abstract: A selection system free of antibiotic resistance genes, which is based on the use of an araD gene as a selection marker carried on a vector which is inserted in a bacterial strain deficient of the araD gene. The araD gene from E. coli encodes the L-ribulose-5-phosphate-4-epimerase. A method of selecting the cells transformed with a plasmid, which contains the araD gene. The non-antibiotic selection marker makes the system suitable for producing therapeutics. The araD gene is not essential for growth of the host but manipulation of it affects the growth under certain selective conditions. Deletion of araD leads to accumulation of substance which is toxic to the host but not to humans. The araD gene is relatively small and therefore a small plasmid may be constructed, which requires less energy for replication, and leads to increased growth rate and yield.Type: ApplicationFiled: September 15, 2004Publication date: February 15, 2007Applicant: FIT BIOTECH OYJ OLCInventors: Tanel Tenson, Silja Laht, Maarja Ado-Jaan, Andres Mannik, Urve Toots, Mart Ustav
-
Publication number: 20050026137Abstract: The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing said vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics containing the vectors, and to therapeutic uses of said vectors. More specifically, the present invention relates to novel vectors comprising (a) an expression cassette of a gene of a nuclear-anchoring protein, which contains (i) a DNA binding domain capable of binding to a specific DNA sequence and (ii) a functional domain capable of binding to a nuclear component and (b) a multimerized DNA sequence forming a binding site for the anchoring protein, and optionally (c) one or more expression cassettes of a DNA sequence of interest. In particular the invention relates to vectors that lack a papilloma virus origin of replication. The nuclear-anchoring protein might be the E2 protein of Bovine Papilloma Virus type 1 or Epstein-Barr Virus Nuclear Antigen 1.Type: ApplicationFiled: May 3, 2002Publication date: February 3, 2005Inventors: Kai Krohn, Vesna Blazevic, Marja Tahtinen, Mart Ustav, Urve Toots, Andres Mannjk, Annamari Ranki, Ene Ustav
-
Publication number: 20030129169Abstract: The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing said vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics, and to therapeutic uses of said vectors. More specifically, the present invention relates to novel vectors comprising an expression cassette of a gene of a nuclear-anchoring protein, which contains a DNA binding domain capable of binding to a specific DNA sequence and a functional domain capable of binding to a nuclear component and a multimerized DNA sequence forming a binding site for the nuclear-anchoring protein, and optionally an expression cassette of a gene, genes or a DNA sequence or DNA sequences of interest. The present invention further relates to DNA vaccines and gene therapeutics containing the novel vectors, to methods for the preparation of the novel vectors and the DNA vaccines and gene therapeutics containing the novel vectors, and to the use the vectors in therapy.Type: ApplicationFiled: May 3, 2002Publication date: July 10, 2003Inventors: Kai Krohn, Vesna Blazevic, Marja Tahtinen, Mart Ustav, Urve Toots, Andres Mannik, Annamari Ranki, Ene Ustav